Rivista di formazione e aggiornamento professionale del pediatra e del medico di base, dal 1982 In collaborazione con l'Associazione Culturale Pediatri

Caso contributivo

PDF MeBrain

Macrotrombocitopenia, dismorfismi facciali e ritardo dello sviluppo psicomotorio: alla scoperta del gene CDC42

Macrotrombocytopenia, facial dysmorphisms and psychomotor development delay: how to discover the CDC42 gene

Elena Fabbri1, Silvia Giardinelli2, Beatrice Filippini1, Pietro Gasperini1, Martina Mazzocco1, Caterina Radice3, Federico Marchetti3, Roberta Pericoli1
1SSDI di Oncoematologia Pediatrica, Ospedale di Rimini, AUSL Romagna
2Scuola di Specializzazione in Pediatria, Università di Ferrara
3UOC di Pediatria e Neonatologia, Ospedale di Ravenna, AUSL della Romagna

Novembre 2022 | DOI: 10.53126/MEBXXVN181

Abstract
Cell Division Control 42 (CDC42) gene encodes for a small GTPase with a fundamental role in controlling intracellular signaling pathway. Gene mutations can cause different phenotypic manifestations, which reflect the variety of the role of this mediator, namely growth failure, facial dysmorphism, intellectual disability, cardiac and nervous system malformations, immunologic and hematologic alterations. The paper describes the case of a 9-year-old female patient presenting with a CDC42 mutation with complex clinical features.
Riassunto
Il gene Cell Division Control 42 (CDC42) codifica per una piccola GTPasi con un ruolo fondamentale nel controllo della via di segnalazione intracellulare. Le mutazioni geniche possono causare diverse manifestazioni fenotipiche, che riflettono la varietà del ruolo di questo mediatore: ritardo della crescita, dismorfismi facciali, disabilità intellettiva, malformazioni del sistema cardiaco e nervoso, alterazioni immunologiche ed ematologiche. Descriviamo il caso di una paziente di sesso femminile di 9 anni, portatrice di una mutazione CDC42 con caratteristiche cliniche complesse.
Contenuto riservato

Per leggere l'articolo è necessario effettuare il login.

Per l'acquisto del singolo articolo scrivi a abbonamenti@medicoebambino.com (la mail si prepara da sola con gli estremi dell'articolo); se accedi, la richiesta parte con un click.

Bibliografia

  1. Szczawinska-Poplonyk A, Ploski R, Bernatowska E, Pac M. A novel CDC42 mutation in an 11-year-old child manifesting as syndromic immunodeficiency, autoinflammation, hemophagocytic lymphohistiocytosis, and malignancy: a case report. Front Immunol 2020;11:318. doi: 10.3389/fimmu.2020.00318.
  2. Takenouchi T, Kosaki R, Niizuma T, Hata K, Kosaki K. Macrothrombocytopenia and developmental delay with a de novo CDC42 mutation: yet another locus for thrombocytopenia and developmental delay. Am J Med Genet A 2015;167A(11):2822-5. doi: 10.1002/ajmg.a.37275.
  3. Uehara T, Suzuki H, Okamoto N, et al. Pathogenetic basis of Takenouchi-Kosaki syndrome: electron microscopy study using platelets in patients and functional studies in a Caenorhabditis elegans model. Sci Rep 2019;9(1):4418. doi: 10.1038/s41598-019-40988-7.
  4. Bucciol G, Pillay B, Casas-Martin J, et al. Systemic inflammation and myelofibrosis in a patient with Takenouchi-Kosaki syndrome due to CDC42 Tyr64Cys mutation. J Clin Immunol 2020;40(4):567-70. doi: 10.1007/s10875-020-00742-5.
  5. Hamada N, Ito H, Shibukawa Y, et al. Neuropathophysiological significance of the c.1449T>C/p.(Tyr64Cys) mutation in the CDC42 gene responsible for Takenouchi-Kosaki syndrome. Biochem Biophys Res Commun 2020;529(4):1033-7. doi: 10.1016/j.bbrc.2020.06.104.
  6. Martinelli, S., Krumbach, Pantaleoni F, et al. Functional dysregulation of CDC42 causes diverse developmental phenotypes. Am J Hum Genet 2018;102(2):309-20. doi: 10.1016/j.ajhg.2017.12.015.
  7. Santoro C, Gaudino G, Torella A, et al.; Telethon Undiagnosed Diseases Program. Intermittent macrothrombocytopenia in a novel patient with Takenouchi-Kosaki syndrome and review of literature. Eur J Med Genet 2021;64(12):104358. doi: 10.1016/j.ejmg.2021.104358.
  8. Ueyama T. Rho-family small GTPases: from highly polarized sensory neurons to cancer cells. Cells 2019;8(2):92. doi: 10.3390/cells8020092.
  9. Melendez J, Grogg M, Zheng Y. Signaling role of CDC42 in regulating mammalian physiology. J Biol Chem 2011;286:2375-81. doi: 10.1074/jbc.R110.200329.
  10. Ueyama T, Sakaguchi H, Nakamura T, et al. Maintenance of stereocilia and apical junctional complexes by CDC42 in cochlear hair cells. J Cell Sci 2014; 127(Pt9):2040-52. doi: 10.1242/jcs.143602.
  11. Lam MT, Coppola S, Krumbach OHF, et al. A novel disorder involving dyshematopoiesis, inflammation, and HLH due to aberrant CDC42 function. J Exp Med 2019;216:2778-99. doi: 10.1084/jem.20190147.
  12. Gernez Y, de Jesus AA, Alsaleem H, et al. Severe autoinflammation in 4 patients with C-terminal variants in cell division control protein 42 homolog (CDC42) successfully treated with IL-1β inhibition. J Allergy Clin Immunol 2019;144(4):1122-25.e6. doi: 10.1016/j.jaci.2019.06.017.
  13. Yang L, Wang L, Kalfa TA, et al. CDC42 critically regulates the balance between myelopoiesis and erythropoiesis. Blood 2007;110(12):3853-61. doi: 10.1182/blood-2007-03-079582.
  14. Govek E-E, Newey SE, Van Aelst L. The role of the Rho GTPases in neuronal development. Genes Dev 2005;19(1):1-49. doi: 10.1101/gad.1256405.
  15. Yang L, Wang L, Geiger H, Cancelas JA, Mo J, Zheng Y. Rho GTPase CDC42 coordinates hematopoietic stem cell quiescence and niche interaction in the bone marrow. Proc Natl Acad Sci U S A 2007;104(12):5091-6.
  16. Mulloy JC, Cancellas JA, Filippi M-D, Kalfa TA, Guo F, Zheng Y. Rho GTPases in hematopoiesis and hemopathies. Blood 2010;115:936-49. doi: 10.1182/blood-2009-09-1981277.
  17. Song W, Liu C, Upadhyaya A. The pivotal position of the actin cytoskeleton in the initiation and regulation of B cell receptor activation. Biochim Biophys Acta 2014;1838:569-78. doi: 10.1016/j.bbamem.2013.07.016.
  18. Guo F, Velu CS, Grimes HL, Zheng Y. Rho GTPase CDC42 is essential for B-lymphocyte development and activation. Blood 2009;114(14):2909-16. doi: 10.1182/blood-2009-04-214676.
  19. Rougerie P, Delon J. Rho GTPases: masters of T lymphocyte migration and activation. Immunol Lett 2012;142(1-2):1-13. doi: 10.1016/j.imlet.2011.12.003.